This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Diamanti-Kandarakis, E. Articles by Duleba, A. J. Search for Related Content PubMed PubMed Citation Articles by Diamanti-Kandarakis, E. Articles by Duleba, A. J.

The Effect of a Pure Antiandrogen Receptor Blocker, Flutamide, on the Lipid Profile in the Polycystic Ovary Syndrome

Laiko Hospital, First Department of Internal Medicine, University of Athens (E.D.-K., G.T.), and Evangelismos Hospital, Second Department of Internal Medicine, University of Athens (A.M., S.R.), Athens, Greece; and the Department of Obstetrics and Gynecology, Yale University School of Medicine (A.J.D.), New Haven, Connecticut 06520

Address all correspondence and requests for reprints to: Dr. Evanthia Diamanti-Kandarakis, First Department of Internal Medicine, Endocrinology Section, University of Athens Medical School, 17 Ag. Thomas Street, Athens 115–27, Greece.

Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting women of reproductive age; it is associated with hyperandrogenism, hyperinsulinemia, and dyslipidemia. This study was designed to assess the long term effects of a pure androgen receptor blocker, flutamide, on the lipid profile in women with PCOS and to examine the possible mechanisms by which androgens may exert their influence. Seventeen women with PCOS (10 obese and 7 lean) were studied. All subjects received a 12-week course of oral flutamide (500 mg/day). The baseline and posttreatment evaluations included lipid profile, androgen levels, insulin sensitivity, and serum catecholamine determinations. The primary outcome was the change in the ratio of low density lipoproteins (LDL) to high density lipoproteins (HDL). Treatment with flutamide was associated with a significant decrease in the LDL/HDL ratio by 23% (P = 0.005), in total cholesterol by 18% (P < 0.0001), in LDL by 13% (P = 0.002), and in triglycerides by 23% (P = 0.002). Flutamide treatment was also associated with a trend toward an increase in HDL (by 14%; P = 0.14). The effects on lipid profile were found regardless of obesity and were not associated with a change in weight. Furthermore, actions of flutamide on lipid metabolism were not associated with significant changes in circulating adrenaline or noradrenaline, glucose metabolism, or insulin sensitivity. This report has demonstrated for the first time that treatment with the pure antiandrogen, flutamide, may improve the lipid profile and that this effect may be due to direct inhibition of androgenic actions.

This article has been cited by other articles:

				R. Pasquali and A. Gambineri Insulin-sensitizing agents in polycystic ovary syndrome. Eur. J. Endocrinol., June 1, 2006; 154(6): 763 - 775. [Abstract] [Full Text] [PDF]

				S. Sam, R. S. Legro, P. A. Essah, T. Apridonidze, and A. Dunaif Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome PNAS, May 2, 2006; 103(18): 7030 - 7035. [Abstract] [Full Text] [PDF]

				L. Ibanez and F. de Zegher Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women Hum. Reprod. Update, May 1, 2006; 12(3): 243 - 252. [Abstract] [Full Text] [PDF]

				A. D. Coviello, R. S. Legro, and A. Dunaif Adolescent Girls with Polycystic Ovary Syndrome Have an Increased Risk of the Metabolic Syndrome Associated with Increasing Androgen Levels Independent of Obesity and Insulin Resistance J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 492 - 497. [Abstract] [Full Text] [PDF]

				M. Hero, O. A. Janne, K. Nanto-Salonen, L. Dunkel, and T. Raivio Circulating Antiandrogenic Activity in Children with Congenital Adrenal Hyperplasia during Peroral Flutamide Treatment J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5141 - 5145. [Abstract] [Full Text] [PDF]

				L. Ibanez, A. M. Jaramillo, A. Ferrer, and F. de Zegher High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception Hum. Reprod., September 1, 2005; 20(9): 2457 - 2462. [Abstract] [Full Text] [PDF]

				S. Sam, R. S. Legro, R. Bentley-Lewis, and A. Dunaif Dyslipidemia and Metabolic Syndrome in the Sisters of Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4797 - 4802. [Abstract] [Full Text] [PDF]

				E Diamanti-Kandarakis, K Alexandraki, A Protogerou, C Piperi, C Papamichael, A Aessopos, J Lekakis, and M Mavrikakis Metformin administration improves endothelial function in women with polycystic ovary syndrome Eur. J. Endocrinol., May 1, 2005; 152(5): 749 - 756. [Abstract] [Full Text] [PDF]

				L. Ibanez, C. Valls, S. Cabre, and F. de Zegher Flutamide-Metformin Plus Ethinylestradiol-Drospirenone for Lipolysis and Antiatherogenesis in Young Women with Ovarian Hyperandrogenism: The Key Role of Early, Low-Dose Flutamide J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4716 - 4720. [Abstract] [Full Text] [PDF]

				K. Unluhizarci, Y. Karababa, F. Bayram, and F. Kelestimur The Investigation of Insulin Resistance in Patients with Idiopathic Hirsutism J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2741 - 2744. [Abstract] [Full Text] [PDF]

				L. Ibanez and F. de Zegher Ethinylestradiol-Drospirenone, Flutamide-Metformin, or Both for Adolescents and Women with Hyperinsulinemic Hyperandrogenism: Opposite Effects on Adipocytokines and Body Adiposity J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1592 - 1597. [Abstract] [Full Text] [PDF]

				V. BRUNI, M. DEI, V. PONTELLO, and P. VANGELISTI The Management of Polycystic Ovary Syndrome Ann. N.Y. Acad. Sci., November 1, 2003; 997(1): 307 - 321. [Abstract] [Full Text] [PDF]

				F. C. W. Wu and A. von Eckardstein Androgens and Coronary Artery Disease Endocr. Rev., April 1, 2003; 24(2): 183 - 217. [Abstract] [Full Text] [PDF]

				L. Ibanez, C. Valls, A. Ferrer, K. Ong, D. B. Dunger, and F. de Zegher Additive Effects of Insulin-Sensitizing and Anti-Androgen Treatment in Young, Nonobese Women with Hyperinsulinism, Hyperandrogenism, Dyslipidemia, and Anovulation J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2870 - 2874. [Abstract] [Full Text] [PDF]

				B. PAIGEN, N. J. SCHORK, K. L. SVENSON, Y.-C. CHEAH, J.-L. MU, F. LAMMERT, D. Q.-H. WANG, G. BOUCHARD, and M. C. CAREY Quantitative trait loci mapping for cholesterol gallstones in AKR/J and C57L/J strains of mice Physiol Genomics, November 9, 2000; 4(1): 59 - 65. [Abstract] [Full Text] [PDF]

				L. Ibáñez, C. Valls, N. Potau, M. V. Marcos, and F. de Zegher Sensitization to Insulin in Adolescent Girls to Normalize Hirsutism, Hyperandrogenism, Oligomenorrhea, Dyslipidemia, and Hyperinsulinism after Precocious Pubarche J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3526 - 3530. [Abstract] [Full Text]

				L. Ibáñez, N. Potau, M. V. Marcos, and F. de Zegher Treatment of Hirsutism, Hyperandrogenism, Oligomenorrhea, Dyslipidemia, and Hyperinsulinism in Nonobese, Adolescent Girls: Effect of Flutamide J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3251 - 3255. [Abstract] [Full Text]

				E. DIAMANTI-KANDARAKIS and E. ZAPANTI Insulin Sensitizers and Antiandrogens in the Treatment of Polycystic Ovary Syndrome Ann. N.Y. Acad. Sci., April 1, 2000; 900(1): 203 - 212. [Abstract] [Full Text] [PDF]

				P. Moghetti, F. Tosi, A. Tosti, C. Negri, C. Misciali, F. Perrone, M. Caputo, M. Muggeo, and R. Castello Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 89 - 94. [Abstract] [Full Text]